Clasado, a global leader in the development of scientifically proven prebiotic ingredients and product solutions for the gut microbiome, has announced that its prebiotic ingredient, Bimuno® GOS, now has 11 self-substantiated health claims available in Colombia.
These 11 health claims are backed by rigorous scientific evidence, enabling the claims to be featured on the packaging of products containing Bimuno GOS in the Colombian health and nutrition market. This also highlights an important expansion to the ongoing regulatory success of Bimuno GOS, which is already recognised as the most widely studied prebiotic ingredient in the GOS (galactooligosaccharides) category. Across various international markets, Bimuno GOS has access to over 80 health claims, underscoring its efficacy and the scientific credibility that consumers seek.
Lucie Nagy, General Counsel at Clasado, commented on this milestone: “Compliance with regulatory standards is paramount in the health and nutrition sector. In short, we’re engaging with a highly proactive market, and health consumers throughout Latin America want to know that there’s robust research and evidence behind the products they buy. These health claims not only reinforce the scientific foundation of Bimuno GOS but also add substantial value for product formulators in Colombia. This achievement is a testament to our exceptional regulatory team’s hard work and dedication.”
Bimuno GOS, with its robust research and regulatory endorsements, provides formulators in Colombia with a powerful tool to attract consumer attention and gain trust. The ingredient has a patented and unique proprietary structure that supports health benefits from a low dose, standing out in the prebiotic market.
The 11 health claims for Bimuno GOS in Colombia include its prebiotic effect, as well as its role in supporting gastrointestinal health and immunity. The substantiated supporting evidence draws from the class-leading portfolio of science behind Bimuno GOS, which includes over 120 publications and more than 20 clinical trials.
This regulatory success, achieved in partnership with CTC Group, distributor of Bimuno GOS in Colombia, is the latest in a series of accomplishments for the ingredient, which includes various health claims in markets around the globe, including the USA, Canada, Asia and Australia.
Andrés Cárdenas, Country Manager at CTC Group, added: “These health claims represent an important milestone for formulators in Colombia seeking to develop science-backed gut health products, to meet rapidly growing consumer demand. The combination of Bimuno GOS’s proven efficacy and clear regulatory status creates fantastic opportunities for brands to connect with health-conscious Colombian consumers, who increasingly understand the importance of supporting their gut microbiome.”
Clasado remains committed to advancing microbiome science and delivering innovative, evidence-based prebiotic solutions that meet consumer health needs.
For more information on the scientific excellence behind Bimuno GOS, click here.